---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-080874"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:11:42.813178+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics prices $125M public offering of common stock and pre-funded warrants

## Summary
- Priced 5,555,557 shares at $13.50/share and pre-funded warrants for 3,703,730 shares at $13.4999.
- Expected gross proceeds of $125M; net proceeds ~$119.8M after underwriting discounts and expenses.
- Net proceeds to fund research, clinical development of STK-001 and STK-002, and other corporate purposes.
- Offering expected to close on April 2, 2024; J.P. Morgan acting as sole book-running manager.

## SEC filing metadata
- accession: 0001193125-24-080874
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312524080874/0001193125-24-080874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312524080874/d807060d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-080874
- JSON: https://secwatch.observer/filing/0001193125-24-080874.json
- Plain text: https://secwatch.observer/filing/0001193125-24-080874.txt

## Key facts
- Material Agreements
  Stoke Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC valued at approximately $119.8 million (effective 2024-03-27).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC
  - Value: approximately $119.8 million
  - Effective: 2024-03-27
  source text: On March 27, 2024, Stoke Therapeutics, Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC as representative of the underwriters named therein (the “Underwriter”), pursuant to which the Company agreed to issue and sell 5,555,557 shares (the “Underwritten Shares”) of its common stock, par value $0.0001 per share (“Common Stock”) to the Underwriter in a public offering at a price of $13.50 per Underwritten Share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000119312524080874/0001193125-24-080874-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.